A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex
Fm. Gordin et al., A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex, CLIN INF D, 28(5), 1999, pp. 1080-1085
Current guidelines suggest that disseminated Mycobacterium avium complex (M
AC) infection be treated with a macrolide plus ethambutol or rifabutin or b
oth. From 1993 to 1996, 198 AIDS patients with MAC bacteremia participated
in a prospective, placebo-controlled trial of clarithromycin (500 mg b.i.d.
) plus ethambutol (1,200 mg/d), with or without rifabutin (300 mg/d). At 16
weeks, 63% of patients in the rifabutin group and 61% in the placebo group
(P = .81) had responded bacteriologically. Changes in clinical symptoms an
d time to survival were similar in both groups. Development of clarithromyc
in resistance during therapy was similar in the two groups; of patients who
had a bacteriologic response, however, only 1 of 44 (2%) receiving rifabut
in developed clarithromycin resistance, vs. 6 of 42 (14%) in the placebo gr
oup (P = .055), Thus, rifabutin had no impact on bacteriologic response or
survival but may protect against development of clarithromycin resistance i
n those who respond to therapy.